Yi Yao | Nanomedicine | Best Researcher Award

Prof. Yi Yao | Nanomedicine | Best Researcher Award

Renmin Hospital of Wuhan University | China

Prof. Yi Yao is a distinguished oncologist, Ph.D., Chief Physician, and Director of the Cancer Center at Renmin Hospital of Wuhan University, China, with a career dedicated to advancing cancer treatment and research. He earned his medical degree and doctorate from Wuhan University and received international training as a Visiting Scholar at the German Cancer Research Center, Heidelberg University, and MD Anderson Cancer Center in the United States. His clinical and research interests focus on tumor radiotherapy and the tumor immune microenvironment, with particular emphasis on how irradiation influences tumor biology, radiotherapy efficacy, and radiation-induced lung injury, including the role of fibroblasts and tumor interstitial fibrosis in treatment outcomes. Prof. Yao has secured major research funding from the National Natural Science Foundation of China, the Hubei Natural Science Foundation, and multiple institutional projects, while building collaborations with world-leading cancer research centers in Germany and the United States. He has published extensively in high-impact journals such as Nature Communications, The EMBO Journal, Journal of Clinical Oncology, Cancer Medicine, Histopathology, Nano Letters, and Frontiers in Immunology, in addition to co-editing oncology volumes and holding software copyrights. Recognized with numerous national, provincial, and institutional awards for his contributions to research, clinical practice, and mentorship, Prof. Yao serves on national and provincial oncology committees, is a member of ASCO and ESMO, and continues to mentor doctoral and master’s students, making lasting contributions to oncology education, clinical innovation, and cancer research.

Profile: Orcid

Featured publications

  • Zhang, H., Chen, L., Li, L., Liu, Y., Das, B., Zhai, S., Tan, J., Jiang, Y., Turco, S., Yao, Y., & Frishman, D. (2025). Prediction and analysis of tumor infiltrating lymphocytes across 28 cancers by TILScout using deep learning. NPJ Precision Oncology, 9(1), 76.

  • Dong, Y., Khan, L., & Yao, Y. (2024). Immunological features of EGFR-mutant NSCLC and clinical practice. Journal of the National Cancer Center, 4(4), 289–298.

  • Yi, L., Wen, Y., Xiao, M., Yuan, J., Ke, X., Zhang, X., Khan, L., Song, Q., & Yao, Y. (2024). The proportion of tumour stroma predicts response to immune checkpoint inhibitor plus chemotherapy in stage IIIB–IV NSCLC. Histopathology, 85(2), 295–309.

  • Yao, Y., Shen, Y., Yao, J. C., & Zuo, X. (2024). Editorial: New advancement in tumor microenvironment remodeling and cancer therapy. Frontiers in Cell and Developmental Biology, 12, 1384567.

  • Li, Y., Chen, J., Wang, B., Xu, Z., Wu, C., Ma, J., Song, Q., Geng, Q., Yu, J., Pei, H., & Yao, Y. (2023). FOXK2 affects cancer cell response to chemotherapy by promoting nucleotide de novo synthesis. Drug Resistance Updates, 67, 100926.

  • Yao, Y., Chu, Y., & Xu, B. (2019). Radiotherapy after surgery has significant survival benefits for patients with triple-negative breast cancer. Cancer Medicine, 8(2), 554–563.

Ms. Moloud Farrokhi | Nanodelivery Awards | Best Researcher Award

Ms. Moloud Farrokhi | Nanodelivery Awards | Best Researcher Award

Ms. Moloud Farrokhi , Albany Medical college, United States

Mouloud Farrokhi is an experienced immunologist and microbiologist specializing in HIV/AIDS research, nanoparticle delivery systems, and viral infections. He is currently pursuing a PhD in Biology with a focus on Immunology and Microbiology at Albany Medical College, USA. Mouloud has a strong academic and professional background, having worked as a research assistant and medical laboratory scientist in Iran and Sweden. His research aims to improve understanding and treatment of viral infections, with significant contributions to HIV drug resistance and oncolytic virus therapy. Mouloud’s work also extends to the development of innovative nanoparticle-based drug delivery systems, offering promising solutions for invasive infections like Aspergillosis. His expertise spans from molecular biology to clinical research, with an emphasis on laboratory techniques like PCR, qRT-PCR, NGS, and CRISPR/Cas9.

Professional Profile:

Google Scholar

Mouloud Farrokhi: A Strong Contender for the Research Best Researcher Award

Mouloud Farrokhi is an exceptional candidate for the Research Best Researcher Award due to his extensive background in immunology, microbiology, and viral infections, as well as his significant contributions to molecular diagnostics and therapeutic innovations. His educational qualifications, research experience, and recognition in the field of medical sciences make him a highly suitable candidate for this prestigious award.

🎓Education:

Mouloud Farrokhi is currently pursuing a PhD in Biology, specializing in Immunology and Microbiology at Albany Medical College, USA (2023–Present). He holds two Master’s degrees: an MSc in Bioscience from the University of Skövde, Sweden (2021–2022), with a thesis on the role of RABL6 in AP3-dependent trafficking, and an MSc in Cellular and Molecular Biology from the Islamic Azad University, Iran (2010–2014), where he researched HIV-1 drug resistance. His undergraduate studies were in Marine Biology at the Islamic Azad University, Tehran, Iran (2003–2008). Mouloud’s extensive education in biological sciences provides a solid foundation for his current research endeavors, focusing on viral infections, molecular diagnostics, and therapeutic innovations.

🏢Experience:

Mouloud Farrokhi has gained extensive experience as a research assistant and medical laboratory scientist. He worked as a Research Assistant at Tehran University of Medical Sciences (2022–2023), where he focused on statistical analysis and NGS (Next Generation Sequencing). He has also served as a Medical Laboratory Assistant at Tehran University of Medical Sciences (2018–2021), where he conducted HIV viral load analysis and COVID-19 testing via qPCR. His previous roles include being a Medical Laboratory Scientist at Dena Lab (2017–2018), where he performed NITP tests and a Research Assistant at Pasteur Institute of Iran (2016–2017), where he researched drug resistance in HIV and HCV. He has also contributed to laboratory work at Keyvan Virology Laboratory, Tehran (2015–2016). Mouloud’s diverse hands-on experience makes him proficient in molecular biology techniques, data analysis, and lab management.

🏅Awards and Honors:

Mouloud Farrokhi’s academic and research achievements are reflected in his high academic standing and contributions to scientific research. His thesis at the University of Skövde received top marks, with a GPA of 3.75, and he has consistently demonstrated excellence throughout his academic career. His research contributions have been recognized in various publications and presentations. Notably, he presented at the International Student Congress in Medical Sciences (ISCOM) in 2017 and at the Upstate New York Immunology Conference (NYIC) in 2024. Mouloud’s work in HIV drug resistance and nanoparticle drug delivery systems has been published in high-impact journals. His dedication to advancing medical science has led to multiple research opportunities, including participation in workshops on gene transfer and vaccine design.

🔬Research Focus:

Mouloud Farrokhi’s research focuses on immunology, microbiology, and the molecular mechanisms underlying viral infections and drug resistance. He investigates the molecular pathways of HIV and other viral infections, focusing on drug resistance mechanisms in HIV-1 and HCV. His research also explores innovative strategies for oncolytic virus therapy and nanoparticle-based drug delivery, with the goal of improving treatment outcomes for invasive infections like Aspergillosis. Additionally, he is involved in genetic analysis and genomic editing technologies such as CRISPR/Cas9. Mouloud’s work integrates molecular diagnostics and therapeutic advancements, contributing significantly to both basic science and clinical applications in virology and immunology.

Publication Top Notes:

  • “Subtype classification of Iranian HIV-1 sequences registered in the HIV databases, 2006-2013”
    • Citations: 31
  • “HIV drug resistance among naïve HIV-infected patients in Iran”
    • Citations: 14
  • “Antiretroviral drug resistance mutations among HIV treatment failure patients in Tehran, Iran”
    • Citations: 11
  • “The first characterization of HIV-1 subtypes and drug resistance mutations among antiretrovirally treated patients in Kermanshah, Iran”
    • Citations: 9
  • “HIV drug resistance and phylogeny profile in naive and antiretroviral-experienced patients in Tehran, Iran”
    • Citations: 8